Study Objectives: Menopausal transition is associated with increased dissatisfaction with sleep, but the effects on sleep architecture are conflicting. This prospective 6-year follow-up study was designed to evaluate the changes in sleep stages and sleep continuity that occur in women during menopausal transition. Methods: Sixty women (mean age 46.0 years, SD 0.9) participated. All women were premenopausal at baseline, and at the 6-year follow-up, women were in different stages of menopausal transition. Polysomnography was used to study sleep architecture at baseline and follow-up. The effects of aging and menopause (assessed as change in serum follicle-stimulating hormone [S-FSH]) on sleep architecture were evaluated using linear regression models. Results: After controlling for body mass index, vasomotor, and depressive symptoms, aging of 6 years resulted in shorter total sleep time (B −37.4, 95% confidence interval [CI] −71.5 to (−3.3)), lower sleep efficiency (B −6.5, 95%CI −12.7 to (−0.2)), as well as in increased transitions from slow-wave sleep (SWS) to wakefulness (B 1.0, 95%CI 0.1 to 1.9), wake after sleep onset (B 37.7, 95%CI 12.5 to 63.0), awakenings per hour (B 1.8, 95%CI 0.8 to 2.8), and arousal index (B 2.3, 95%CI 0.1 to 4.4). Higher S-FSH concentration in menopausal transition was associated with increased SWS (B 0.09, 95%CI 0.01 to 0.16) after controlling for confounding factors. Conclusions: A significant deterioration in sleep continuity occurs when women age from 46 to 52 years, but change from premenopausal to menopausal state restores some SWS.
INTRODUCTION
Perceived sleep problems affect up to half of the women during menopausal transition. 1 This has been confirmed in several large longitudinal studies. [2] [3] [4] However, the evidence for changes in sleep architecture during menopausal transition is inconsistent. 5, 6 There are only a few polysomnographic (PSG) sleep studies assessing sleep architecture in premenopausal and postmenopausal women, all with cross-sectional design. Three of the studies found no differences in sleep architecture based on menopausal state. [7] [8] [9] In a large epidemiological study, sleep architecture was better in perimenopausal and postmenopausal women compared to premenopausal women. 6 One study in patients with insomnia found worsening sleep architecture in peri-and postmenopausal women compared to premenopausal women. 10 The concentration of serum follicle-stimulating hormone (S-FSH) is considered as a marker of menopausal state. 11 Accordingly, an association between S-FSH concentration and sleep architecture has been evaluated in a few studies assessing the effect of menopause on sleep. A cross-sectional substudy of the Study of Women's Health Across the Nation showed that more rapid rate of S-FSH change was associated with higher percentage of slow-wave sleep (SWS) and longer total sleep time (TST) in pre-, peri-, and postmenopausal women. 12 Another cross-sectional study on pre-and perimenopausal women with and without insomnia found that in perimenopausal noninsomniacs higher S-FSH concentration was associated with increased WASO, awakenings, and arousals after adjusting with age, body mass index (BMI), and hot flashes. In premenopausal noninsomniacs, higher S-FSH concentration was associated with increased WASO and light sleep. However, in perimenopausal women with insomnia, S-FSH did not correlate with PSG-measured sleep. 13 Poor sleep is reported especially in the presence of vasomotor symptoms. 2, 4, 14, 15 Nevertheless, even today the researchers are not unanimous about the primary cause of menopausal sleep disturbance. In addition to fluctuations and decrease in reproductive hormone concentrations, aging itself, 16 depressive symptoms, 17, 18 sleep-disordered breathing, primary sleep disorders, other systemic diseases and/ or their medications as well as psychosocial or behavioral factors may contribute to sleep impairment. [19] [20] [21] Hence, the etiology of sleep disturbance in menopausal transition is probably multifactorial, which may challenge diagnosis and treatment.
Previous PSG sleep studies with conflicting results are cross-sectional. The present study was aimed to evaluate sleep architecture with PSG during menopausal transition with a prospective 6-year follow-up design. The principal aim was to elucidate the effect of hormonal changes and aging on sleep. We hypothesized that menopausal transition and aging both contribute to deterioration in sleep architecture.
METHODS
We used the data from a larger prospective "Woman 46" study, which investigates sleep and cardiovascular risk factors in a middle-aged female population. Women were recruited through newspaper announcements in the Turku city area in Finland. The main exclusion criteria included the presence of coronary heart disease, respiratory insufficiency, sleep apnea, neurological disease, liver disease, malignancies, and alcohol abuse. A total of 147 women, aged 46 years, participated in the study at baseline and were invited to the follow-up study after 6 years. We selected this age-group, since the average menopause age in Finland is 51 years, 22 and thus, at the follow-up time point, part of the women were likely to have reached the menopause. The longitudinal study design enabled us to assess the interactions of hormonal state and age with sleep. Of the 147 women who took part in the baseline study, 37 refused from the follow-up study. Of the remaining participants, 91 women were premenopausal and eligible for the study. The follow-up sleep data from 20 women were considered technically insufficient to be included. In addition, two women with missing S-FSH value at follow-up and 9 women using hormone replacement therapy at follow-up were excluded. The remaining 60 women were included in the present study ( Figure 1 ). According to their S-FSH concentrations, all women were premenopausal (FSH <20 IU/L) at baseline. At the 6-year follow-up, the women were in different states of menopausal transition. Of the entire sample, 23 women had amenorrhea ≥12 months, 12 women had irregular menstruation, 12 women had regular menstruation, 6 had had hysterectomy, and 7 women had hormonal intrauterine device (Mirena ® , which usually causes amenorrhea) at follow-up. At baseline, four (6.7%) women of the entire sample used central nervous system (CNS) affecting medication (nortriptyline, amitriptyline, gabapentin, doxepine, and pramipexole). At the 6-year follow-up, 12 (20.0%) women had medication with CNS effects. Medication consisted of pramipexol (2 patients), escitalopram (4 patients), gabapentin (2 patients), amitriptyline (2 patients), sertraline (1 patient), clonatsepam (1 patient), venlafaxine (1 patient), and bubrenorfin (1 patient). The study had the approval of the Ethics Committee of the Hospital District of Southwest Finland. Written informed consent was obtained after oral and written information from all participants.
The overnight PSG recordings were performed in sleep laboratory, including continuous monitoring of electroencephalogram (EEG; C3/A2, C4/A1, O1/A2, and O2/A1), two electro-oculograms, and one submandibular electromyogram (Embla®, Medcare Flaga hf. Medical Devises, Reykjavik, Iceland). Nasal inspiratory airflow was measured with nasal prongs connected to the pressure transducer. Arterial oxyhemoglobin saturation (SaO 2 ) was measured with a finger probe pulse oximeter (Nonin® oximeter built in with Embla®/Somnologica system; MedcareFlaga hf, Reykjavik, Iceland).
We used conventional criteria 23 to score non-rapid eye movement (NREM) sleep, REM sleep, and wake time after sleep onset (WASO). NREM sleep consisted of stage 1 (S1), stage 2 (S2), and SWS (stage 3 [S3] and stage 4 [S4] combined). The R-K criteria were used instead of the American Academy of Sleep Medicine (AASM) criteria 24 for scoring, since the AASM criteria were not published at the time of the study initiation. All recordings were visually scored in 30-second epochs by an experienced sleep technician. For quality control, all recordings were rescored by a senior scorer (S-LH). Sleep stages (S1, S2, SWS, and REM) were expressed as percentages of TST. REM and SWS periods were calculated. Sleep latency (SL) was determined as the time in minutes from lights off until an occurrence of three consecutive S1 epochs or as one epoch of any other sleep stage. Sleep onset latencies to S1 and S2 sleep were defined as the times in minutes from lights off to the first 30 seconds of S1 and S2 sleep, and sleep onset latencies to SWS and REM sleep as the times in minutes from sleep onset to the first 30 seconds of the respective sleep stage. WASO and TST were expressed in minutes. Sleep efficiency (SE) was calculated by dividing TST by the time in bed (lights off to lights on) and expressed as percentage. Sleep stage transitions per an hour, the number of sleep stage transitions from SWS to wake per night, and the number of awakenings and arousals per an hour were calculated. An awakening was classified as entering wake stage for at least 15 seconds from any sleep stage, and an arousal according to the ASDA criteria as EEG alpha-activity for at least 3 seconds. 25 The sum of awakenings per hour and arousals per hour were combined to arousal index (ARI).
Either C3-A2 or C4-A1 EEG derivation was used to calculate slow-wave activity (SWA; 0.75-4 Hz) during S2, S3, and S4 NREM sleep. First, all EEG artifacts (periods of movements and eye movements) and event-triggered slow waves with increased muscle tone were visually identified and removed from the calculations. 26 In six patients, both C3-A2 and C4-A1 channels contained excessive alternating artifacts, and the recordings from these patients were omitted from the spectral analysis. Forty-three of all PSGs were initially recorded with a 100 Hz sampling rate and were upsampled to 200 Hz before spectral computations. In the upsampling procedure, a zero was added after each sample of the 100 Hz signal, thereafter this sequence was filtered with a 401-tap finite impulse response (FIR) filter (designed to have a band-pass from 0 to 45 Hz and −3 dB point at 46.7 Hz and stopband from 49.4 to 100 Hz with over 60 dB attenuation in all that range), and the obtained signal samples at 200 Hz were multiplied by two. In the spectral computations, EEG signal segmentation of 2-s duration with 50% overlapping was used. The 2-second long signal segment was centered at the kth second in the recording. After the mean removal, the 2-second long EEG signal segment was windowed with a 400-point long Hanning window function, denoted as w n , where n = 1,…, L, and L = 400. This sequence was then zero-padded to a length of 1024, and the fast Fourier transform was taken of the entire sequence providing the complex-valued spectrum, denoted as R(f) = X(f) + jY(f), where f denotes the frequency and j denotes the imaginary unit. Thereafter, the spectrum was scaled to the power spectral density, denoted as P(f), as follows (where ‖ ‖ indicates vector norm and f s the sampling frequency of 200 Hz):
The mean value of the power spectral density P(f) in the frequency band of 0.75-4 Hz was extracted at each second k (frequency resolution of the P(f) was 0.195 Hz) and multiplied by 1 Hz providing the SWA power/3.25 (µV 2 ). And finally, the average value of all these computed SWA power values during the night (excluding artifacts) was extracted, providing the time-average SWA power (µV 2 ) during the night. The overnight mean and minimum of the SaO 2 level, the percentage of SaO 2 under 90%, and the episodes of arterial oxyhemoglobin desaturation of 4% units or more per hour (ODI 4 ) were calculated automatically with the default settings in Somnologica, after manually removing possible artifacts. Apnea-hypopnea index (AHI) was determined visually. Apnea was scored when the amplitude of nasal flow signal decreased at least 90% from the baseline and the event lasted 10 seconds or more. Hypopnea was scored when the amplitude of nasal flow signal decreased at least 30% from the baseline, lasted 10 seconds or more, and was associated with a minimum of 4% desaturation from the baseline before the event. According to our recordings, 13 (21.7%) women had AHI >5 and 7 (11.7%) women had AHI >10.
The S-FSH sample was taken in the morning, on the same day prior to the sleep study and in premenopausal women at the beginning of the follicular phase (days 1-7 of the menstrual cycle). Concentration of S-FSH was measured with time-resolved immunofluorometric assay (AutoDELFIA ® ; PerkinElmer Life and Analytical Sciences, Wallac Oy, Turku, Finland). At baseline and at follow-up, height and weight were measured, and BMI was calculated accordingly. Of the other background variables, marital status was defined as married, single, divorced, or widowed and education was graded to lower (elementary school to middle school) or higher (middle school + college level training to academic education). Vasomotor symptoms were assessed with two questions: "During the past six months, have you suffered from (1) night sweats or (2) hot flashes?" In both questions, severity of the symptoms ranged from 1 to 4 (1 = seldom or never, 2 = once a month, 3 = once a week, and 4 = almost daily). To study the presence of current depressive symptoms, we used the 21-item Beck Depression Inventory (BDI), 27 where higher scores indicated more severe depressive symptoms.
Statistical Analyses
Within-patient changes in patient characteristics and PSG variables between baseline and follow-up were compared with paired t-test for continuous variables (PSG variables, age, BMI and BDI total score) and McNemar-Bowker test for categorical variables (education, marital status, night sweats, and hot flashes). In order to study the within-patient changes in PSG variables, an ordinary least squares linear regression model was fitted for each PSG variable using change in time (6 years, constant) and change in S-FSH concentration (continuous) as covariates. This allowed us to model the effect of aging simultaneously with the effect of menopausal change and to compare their individual effects on the change in the PSG variables. Effect sizes were given by the regression models as unstandardized B coefficients, which signify how much a given PSG variable changes when time is increased by 6 years or when S-FSH concentration is increased by 1 IU/L. Adjusted regression coefficients were obtained by including changes in BMI, night sweats, hot flashes, and BDI total score as covariates in the regression models. The p values <.05 were considered statistically significant, and all p values were two-sided. Statistical analyses were performed with IBM SPSS version 23 with standard packages.
RESULTS
The characteristics of the sample are described in Table 1 . As expected, age and S-FSH concentration were higher as well as night sweats and hot flashes more frequent at follow-up than at baseline. In addition, BMI increased during the follow-up period.
During the follow-up period, SL, sleep onset latencies to S1 and S2, and sleep stage transitions per hour decreased in the entire sample. Instead, sleep onset latency to REM, transitions from SWS to wake, WASO, awakenings, and ARI increased. In addition, AHI and ODI 4 increased during the follow-up period. (Table 2 ).
According to the regression analysis, both aging and S-FSH concentration had influence on PSG variables. Aging of six years resulted in a decrease of 12.2 min in SL, a decrease of 12.8 min in sleep onset latency to S2, an increase of 0.9 in transitions from SWS to wake per night, an increase of 27.3 min in WASO, an increase of 1.4 in awakenings per hour, an increase of 2.4 units in ARI, and an increase of 5.6 units in AHI. An increase of 1 unit in S-FSH concentration resulted in an increase of 0.09% in SWS and an increase of 0.02 in SWS periods. However, neither aging nor S-FSH concentration were associated with SWA (Table 3) .
After adjusting the regression analysis with BMI, night sweats, hot flashes, and BDI total score, aging and S-FSH concentration still had effect on PSG variables. Aging of 6 years resulted in a decrease of 37. Table 3 ).
DISCUSSION
Our 6-year follow-up study allowed us to investigate separately the effects of aging and menopausal hormonal changes on sleep architecture during menopausal transition. Both aging and menopause, defined with S-FSH concentration, had an impact. Irrespective of menopausal hormonal state, aging resulted in deterioration in sleep architecture: TST shortened, SE decreased, and sleep was increasingly fragmented. Unexpectedly, higher S-FSH concentration was associated with higher proportion of SWS. Although this finding might occur by chance, it could also signify a counterbalance to age-related sleep deterioration.
To best of our knowledge, there are no previous reports from prospective follow-up cohorts addressing the impact of menopause on sleep architecture in healthy women and only some cross-sectional studies with inconsistent results. Kalleinen et al. found in their study with three cross-sectional populations (young [22-26 years] , premenopausal [45-51 years] , and postmenopausal [59-71 years] women) that sleep architecture did not differ between pre-and postmenopausal women. However, compared to young women, pre-and postmenopausal women had shorter TST, lower SE, less SWS, and more wake state. 9 A study comparing pre-and postmenopausal women aged 46-51 years 8 or another comparing early postmenopausal women to late postmenopausal women, aged 50-65 years, 28 found no differences in sleep architecture. Instead, a large cross-sectional study with 589 premenopausal, perimenopausal, and postmenopausal women, aged 30-60 years, reported worse sleep architecture in premenopausal women compared to postmenopausal women; premenopausal women had lower SE, less SWS, and more S2 than postmenopausal women. However, peri-and postmenopausal women were twice as likely to be dissatisfied with their subjective sleep quality compared to premenopausal women. 6 A smaller study observed longer SWS latency and more S1 sleep in premenopausal women (aged 45-51 years) compared to postmenopausal women (aged 47-56 years). 29 Likewise, a cross-sectional substudy of the SWAN cohort with 365 pre-, peri-, and postmenopausal women, aged 48-59 years, showed that more rapid rate of S-FSH change was associated with higher percentage of SWS and longer TST. In that study, S-FSH concentration was measured annually 7 years prior and the last time 3-6 months prior to the sleep recording. 12 Instead, de Zambotti and coworkers found in their cross-sectional study that in perimenopausal noninsomniacs, higher S-FSH concentration was associated with WASO, awakenings, and arousals after adjusting with age, BMI, and hot flashes and in premenopausal noninsomniacs with higher proportion of WASO and N1 sleep. 13 We essentially confirmed the results of Young and coworkers, as well as of Sowers and colleagues, showing the association between menopausal transition and an increase in SWS. 6, 12 However, in our study, TST was shorter, SE lower, and sleep more fragmented, despite the menopausal hormonal state at follow-up.
The reasons for increased SWS in menopausal transition are not known. One possible explanation could be an increase in core body temperature in women with higher S-FSH concentration. Previously, it has been shown that a rise in core body temperature results in an increase in the amount of SWS. 30, 31 By aging 32 and in connection with menopause, 33, 34 an alteration in thermoregulation has been suggested. The increase in SWS could also indicate sleep deprivation; however, this was not supported by any decrease in SL to SWS. We propose that menopausal transition allows for an increase in SWS as an adaptive change to counteract the age-related sleep fragmentation.
It has been suggested that conventional sleep stage scoring may underestimate age-related changes in sleep. 35, 36 However, only a few cross-sectional studies have evaluated the effects of age on SWA in midlife women. In our study, aging or changes in S-FSH concentration did not impact SWA. This is in line with our previous study conducted in young, pre-, and postmenopausal women. 9 No differences in SWA between middle-aged pre-and late postmenopausal women were found; instead young women aged 22-26 years had significantly higher SWA compared to pre-and postmenopausal women. 9 Further, in a study of Kravitz et al., vasomotor and mood symptoms did not alter delta sleep ratio in menopausal transition. 37 In a study with 100 patients (of 47 women) aged 20-60 years, 36 as well as in a recent study of 211 Swedish women aged 22-71 years, 35 older age was associated with lower SWA. The wider age range in these studies compared to our study or to that of Kalleinen and coworkers 9 is likely to explain the discrepancy in the impact of aging on SWA. Further, our study is the only one with a prospective follow-up design.
Changes in sleep architecture with advancing age are well described in the literature. Older adults spend more time in the lighter sleep stages and less time in SWS and REM sleep compared to younger adults. 16, 38, 39 In addition SE and REM latency decrease while SL and WASO increase. 16, 38, 39 Furthermore, more frequent transitions from sleep stage to another and more frequent arousals result in more fragmented sleep and less satisfaction of perceived sleep. 38 Our results are in line with the previous studies in terms of age-related changes in sleep architecture. Aging of 6 years was associated with more frequent transitions from SWS to wake and increased WASO, awakenings, and ARI. These changes remained significant after controlling for confounding factors. In addition, after adjusting, aging was linked with decreased TST and SE. Furthermore, aging resulted in a shortening of SL and sleep onset latency to S2, possible as an indicator of sleep deprivation, although these findings disappeared after adjustment. It is also speculated that older persons may have a reduced homeostatic drive and desynchronization of the circadian rhythm, which both interfere with their sleep. 38 Further, the concentrations of sleep-related hormones, like growth hormone, prolactin, 40 and melatonin 41 are also lower in older patients. Additionally, primary sleep disorders, such as insomnia, sleep-disordered breathing, restless legs syndrome, periodic leg movement syndrome, and circadian rhythm sleep disorders, as well as other medical and psychiatric comorbidities and associated medications, possibly impairing sleep are more common in older adults. 20, 38 However, women in our study were relatively healthy, and thus comorbidity was unlikely to contribute to our findings.
In our study, the impact of vasomotor symptoms on sleep architecture was unexpectedly mild. After adjustment with vasomotor symptoms, sleep fragmentation was still considerably associated with aging. Many studies have endorsed the relationship between perceived vasomotor symptoms and perceived sleep disturbances. 4, 42, 43 However, the results in objective sleep studies have been inconsistent, depending on subjective or objective measurements of vasomotor symptoms. 44 In a study of Young et al., sleep variables did not differ in menopausal women, whether or not the women reported hot flashes. 6 We used also subjective measurement of vasomotor symptoms and gained essentially similar results. In contrast, Thurston and coworkers found that more vasomotor symptoms recalled upon waking were associated with lower SE, higher WASO, and longer SL. 45 Vasomotor symptoms can be recorded objectively by measuring the sternal skin conductance. 46 Baker and coauthors reported that the presence of objectively measured hot flashes predicted the frequency of awakenings. 47 Similarly, some earlier studies showed a deleterious effect of objectively measured hot flashes on sleep parameters, 48, 49 while others found no association. 8 There is compelling evidence that the prevalence of sleep-disordered breathing (SDB) increases during menopausal transition, when women lose the protective effect of female sex hormones. [50] [51] [52] After adjusting for age, BMI, and other confounding factors, compared to premenopausal women, odds ratio for sleep apnea was more than twofold in postmenopausal women in the Wisconsin Sleep Cohort Study. 52 In our study, however, increased AHI seemed to be age dependent rather than FSH dependent, although also this association lost significance after controlling for BMI and other confounding factors.
Several limitations in our study set up must be considered, when interpreting our findings. The sample size was rather small, and thus the results should be repeated in larger study groups. Further, we did not use the Stages of Reproductive Aging Workshop (STRAW) criteria 11 to group women into different menopausal states but used instead S-FSH concentration as a continuous marker of menopausal transition. We evaluated vasomotor symptoms subjectively, which may result in underestimation of their frequency. 46 In addition, we did not evaluate effects of additional stressors (e.g., marital problems, empty nest syndrome, loss of significant others, and growing demands at work), which are common in midlife women. 20 Age-related changes in circadian characteristics might have influence on age-related changes in sleep architecture. However, we did not have data on the morningness-eveningness types in our study cohort. Finally, we did not have an adaptation night before the sleep recordings. The first night effect on sleep is a wellknown phenomenon, 53 shown also in peri-and postmenopausal women. 54 However, some studies have proposed that this effect involves even up to four consecutive nights. 55 A notable strength of our study was the prospective 6-year follow-up design. In addition, we analyzed S-FSH concentration continuously, using it as a marker of reproductive aging. These facts permitted us to evaluate the effects of both aging and hormonal changes separated in a design with repeated measures. We used PSG, the golden standard, to measure sleep. To our knowledge, this was the first longitudinal PSG study focusing on the impact of menopausal transition on sleep. Finally, our cohort was relatively healthy and was homogenous in terms of age and demographic factors.
CONCLUSION
Both aging and an increase in S-FSH concentration have impact on sleep architecture. The independent age-related changes include shorter TST, lower SE, and greater sleep fragmentation. Increasing S-FSH, a marker of transition from premenopause to postmenopause, is associated with higher proportion of SWS. Although the physiology behind this phenomenon remains to be demonstrated, it may represent a mechanism to cope with increased age-related sleep fragmentation. Table 3 . SWS, slow wave sleep; FSH, follicle stimulating hormone level.
